Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

StemCells, Inc. Executive Vice President Ann Tsukamoto, Ph.D., to Make Keynote Address at 2013 Stem Cell Meeting on the Mesa's



StemCells, Inc. Executive Vice President Ann Tsukamoto, Ph.D., to Make Keynote
Address at 2013 Stem Cell Meeting on the Mesa's Scientific Symposium

NEWARK, Calif., Oct. 10, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM), the leading stem cell company developing novel cell-based
therapeutics for disorders of the central nervous system, announced today that
Ann Tsukamoto, Ph.D., Executive Vice President, Scientific and Strategic
Alliances at StemCells, will make the keynote address at the Scientific
Symposium of the 2013 Stem Cell Meeting on the Mesa, to be held October 14-16
in La Jolla, Calif. In her address, "Human Neural Stem Cells from Discovery to
Clinic," Dr. Tsukamoto will describe the compelling preclinical data that
underlie the Company's clinical trials targeting disorders in the brain,
spinal cord, and eye, and the encouraging early data from these clinical
trials. Dr. Tsukamoto is scheduled to speak at 8:05 a.m. Pacific Time on
October 16, at the Salk Institute for Biological Studies.

"Harnessing the potential of cell-based therapy presents many challenges,"
said Dr. Tsukamoto. "We at StemCells have taken a meticulous approach to
developing our proprietary neural stem cell technology. We have carefully
followed the science, and have generated and published a robust body of
scientific data, including a number of preclinical proof-of-principle studies
in well-accepted animal models. The early clinical data from a number of our
Phase I/II trials is encouraging as the data is beginning to confirm much of
what we have seen in the animal models."

Dr. Tsukamoto has been working on stem cells for over 25 years. She joined
StemCells in 1998, and under her direction, the Company isolated its
proprietary HuCNS-SC^® cells (purified human neural stem cells) and
successfully transitioned into clinical development for a range of CNS
indications. Prior to joining the Company, Dr. Tsukamoto was a co-discoverer
of the human hematopoietic stem cell and is a named inventor on seven issued
US patents.

The Stem Cell Meeting on the Mesa is a three-day conference organized by the
Sanford Consortium for Regenerative Medicine, the California Institute for
Regenerative Medicine (CIRM), and the Alliance for Regenerative Medicine
(ARM). The conference is aimed at bringing together senior members of the
regenerative medicine industry with the scientific research community to
advance stem cell science into cures. The conference's nationally recognized
Scientific Symposium, which will be held on October 16, is attended by leading
scientists and researchers and will showcase leading academic research in the
field of regenerative medicine. The conference's Regen Med Partnering Forum,
the only partnering meeting organized specifically for the regenerative
medicine and advanced therapies industry, will be held October 14-15. Please
visit http://stemcellmeetingonthemesa.com/ for more information.

StemCells, Inc. is a sponsor of the 2013 Stem Cell Meeting on the Mesa.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's proprietary HuCNS-SC^® cells (purified human
neural stem cells) are currently in development as a potential treatment for a
broad range of central nervous system disorders. In a Phase I clinical trial
in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in
children, the Company has shown preliminary evidence of progressive and
durable donor-derived myelination in all four patients transplanted with
HuCNS-SC cells. The Company is conducting a Phase I/II clinical trial in
chronic spinal cord injury in Switzerland, Canada and the United States, and
has reported positive interim data for the first three patients. The Company
is also conducting a Phase I/II clinical trial in dry age-related macular
degeneration (AMD) in the United States.  In addition, the Company is pursuing
preclinical studies in Alzheimer's disease, with support from the California
Institute for Regenerative Medicine (CIRM). StemCells also markets stem cell
research products, including media and reagents, under the SC Proven^®
brand. Further information about StemCells is available at
http://www.stemcellsinc.com.

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein. These
statements include, but are not limited to, statements regarding the clinical
development of the Company's HuCNS-SC cells; the Company's ability to
commercialize drug discovery and drug development tools; and the future
business operations of the Company. These forward-looking statements speak
only as of the date of this news release. The Company does not undertake to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements reflect
management's current views and are based on certain assumptions that may or
may not ultimately prove valid. The Company's actual results may vary
materially from those contemplated in such forward-looking statements due to
risks and uncertainties to which the Company is subject, including the fact
that additional trials will be required to demonstrate the safety and efficacy
of the Company's HuCNS-SC cells for the treatment of any disease or disorder;
uncertainties regarding the ability of preclinical research, including
research in animal models, to accurately predict success or failure in
clinical trials; uncertainties regarding the Company's ability to obtain the
increased capital resources needed to continue its current and planned
research and development operations; uncertainty as to whether HuCNS-SC cells
and any products that may be generated in the future in the Company's
cell-based programs will prove safe and clinically effective and not cause
tumors or other adverse side effects; uncertainties regarding the Company's
ability to commercialize a therapeutic product and its ability to successfully
compete with other products on the market; and other factors that are
described under the heading "Risk Factors" in the Company's Annual Report on
Form 10-K for the year ended December 31, 2012 and in its subsequent reports
on Forms 10-Q and 8-K.

CONTACT: Rodney Young
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
        
         Ian Stone
         Russo Partners
         (619) 308-6541

company logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement